MARKET

LGND

LGND

Ligand Pharma
NASDAQ
199.59
-0.03
-0.02%
After Hours: 199.59 0 0.00% 16:10 04/02 EDT
OPEN
197.54
PREV CLOSE
199.62
HIGH
201.42
LOW
194.67
VOLUME
221.93K
TURNOVER
--
52 WEEK HIGH
227.92
52 WEEK LOW
93.58
MARKET CAP
3.98B
P/E (TTM)
32.55
1D
5D
1M
3M
1Y
5Y
1D
Ligand director John W. Kozarich disposes of shares worth $0.1 million
Reuters · 1d ago
Ligand CLO Andrew Reardon disposes of LGND shares worth $0.99 million
Reuters · 1d ago
Major Insider Move at Ligand Pharma Sparks Investor Buzz
TipRanks · 3d ago
Ligand director John LaMattina disposes of common shares worth $0.43 million
Reuters · 3d ago
Weekly Report: what happened at LGND last week (0323-0327)?
Weekly Report · 5d ago
Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know
NASDAQ · 03/27 23:40
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Ligand Pharma (LGND)
TipRanks · 03/26 15:30
Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to VP of Portfolio Strategy and Investments
Reuters · 03/26 11:03
More
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.

Webull offers Ligand Pharmaceuticals Inc stock information, including NASDAQ: LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.